AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (784.6 KB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Rapid Communication | Open Access

In-depth profiling of tumor tissue derived from malignant pleural mesothelioma patients identifies potential biomarkers predicting response to immune-checkpoint inhibitor therapy

Dmitrii Sheka,b,cBo Gaoc,d,eHema Mahajand,e,fAdnan Nagrialc,d,eMatteo S. Carlinoc,d,e,gFabio Lucianih,iScott A. Reada,b,cGolo Ahlenstiela,b,c( )
Blacktown Clinical School, Western Sydney University, Sydney, NSW 2148, Australia
Westmead Institute for Medical Research, Sydney, NSW 2145, Australia
Blacktown Mt Druitt Hospital, Sydney, NSW 2148, Australia
Westmead Hospital, Sydney, NSW 2145, Australia
Westmead Clinical School, University of Sydney, Sydney, NSW 2145, Australia
Institute of Clinical Pathology and Medical Research, Sydney, NSW 2145, Australia
Melanoma Institute Australia, Sydney, NSW 2065, Australia
School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia
Garvan Institute for Medical Research, Sydney, NSW 2010, Australia

Peer review under responsibility of Chongqing Medical University.

Show Author Information

References

1

Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488-499.

2

Shek D, Gloss B, Lai J, et al. Identification and characterisation of infiltrating immune cells in malignant pleural mesothelioma using spatial transcriptomics. Methods Protoc. 2023;6(2):35.

3

Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550.

4

Jiang X, Zhou T, Xiao Y, et al. Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. OncoImmunology. 2016;5(9):e1211219.

5

Midro AT, Panasiuk B, Tümer Z, et al. Interstitial deletion 9q22.32-q33.2 associated with additional familial translocation t(9;17)(q34.11;p11.2) in a patient with Gorlin-Goltz syndrome and features of Nail-Patella syndrome. Am J Med Genet. 2004;124A(2):179-191.

Genes & Diseases
Article number: 101189
Cite this article:
Shek D, Gao B, Mahajan H, et al. In-depth profiling of tumor tissue derived from malignant pleural mesothelioma patients identifies potential biomarkers predicting response to immune-checkpoint inhibitor therapy. Genes & Diseases, 2024, 11(6): 101189. https://doi.org/10.1016/j.gendis.2023.101189

59

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Altmetrics

Received: 25 June 2023
Published: 03 December 2023
© 2023 The Authors.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Return